ichorbio Citations (Resources)

Mechanistic insights supported by ichorbio’s in vivo PD-1 antibodies

A recent study utilizing the Bovine Viral Diarrhea Virus (BVDV) model has provided crucial insights into strategies for overcoming infection-induced...

The efficacy of therapeutic monoclonal antibodies (mAbs) in oncology often hinges on their ability to engage innate immune effector cells, primarily Natural Killer (NK) cells and macrophages, through the Fc gamma receptor IIIa (CD16a). This engagement triggers...

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer mortality, frequently characterized by poor response rates to immune checkpoint inhibitors (ICIs). A growing body of evidence implicates nutritional factors and altered...

A recent article published in Nature (Vol. 631, 23 July 2025) reveals that antibody-mediated humoral immunity, specifically the presence of autoantibodies (AAbs), can significantly influence the effectiveness of checkpoint immunotherapy (CPI) for cancer. The study, which used a high-throughput...

A recent study published in 

Molecular Therapy: Oncology (Vol. 33, Sept 2025) demonstrates the therapeutic potential of a novel oncolytic vaccinia...

Introduction...

Introduction

Dietary fiber has long been heralded as a health-promoting nutrient, with recent studies suggesting it may enhance the efficacy of immune checkpoint blockade (ICB) therapies by modulating the gut microbiome. However...